PharmaCyte Biotech Inc (PMCB)

[Peacefulwendy]

Completely different forum. He is talking trial design in this interview. He is not addressing anything that has to do with a specific drug, trial or company. Great read, however, to provide insight as to why TD2 is being so detailed in the preclinicals.

"Medelis: So the complete phase Ib sounds like a win-win-win since there is benefit to patients, investigators, and sponsors?

Dr. Von Hoff: Approaching the phase Ib as not just a toxicity trial but also a therapeutic opportunity is actually a quadruple win. CMOs benefit on the business side; they get better data faster, helping to drive fundraising and corporate development. Investigators have an opportunity to make an impact, delivering better care and the chance for a better outcome. And sponsors get answers faster and with less bureaucratic hassle since trial management is streamlined.

Last but not least, the complete phase Ib is an important opportunity to truly help patients. And in the end, that’s the most valuable win of all."

http://www.medelis.com/clinical-cancer-research-abstracts/complete-phase-ib-trial-design/